Search Results

Blood Cancer - General Information

In addition to our programs and services for blood cancer patients, families and caregivers, The Leukemia & Lymphoma Society (LLS) is pleased to offer an extensive directory of national and international resources. It may be helpful for you to browse each section to discover all that's offered.

Blood Cancer Treatment

Health Insurance - US

Patient and Caregiver Support and Counseling

Patient Well-Being During Treatment

Professional Organizations for Health Care Providers

Related Diseases and Conditions

Resources - Canada and International

Digital Resources

Fertility and Pregnancy

In addition to our programs and services for blood cancer patients, families and caregivers, The Leukemia & Lymphoma Society (LLS) is pleased to offer an extensive directory of national and international resources. These organizations can help with cancer-related issues like financial assistance, support and counseling, assistance with transportation, and summer camps.

Financial Resources

For information about LLS's financial assistance programs, click here.

Other Helpful Organizations

In addition to our programs and services for blood cancer patients, families and caregivers, LLS is pleased to offer an extensive directory of national and international resources. These organizations can help with cancer-related issues like financial assistance, support and counseling, assistance with transportation, etc. It may be helpful for you to browse through each section to discover all that is offered.

LLS ANSWERS 10 QUESTIONS ABOUT COVID-19 VACCINES

Support Groups

Reach Out to Others for Support

The Leukemia & Lymphoma Society's (LLS's) support groups are the perfect place to talk with other people affected by blood cancers, including patients, family members and caregivers. The groups provide mutual support and offer the opportunity to discuss anxieties and concerns with others who share the same experiences. This sharing strengthens the family bond and enhances everyone's ability to cope with cancer.

Assistance with Finding Low-Cost Prescriptions

Please note that these resources are regularly reviewed to ensure that links still work correctly and that the resources listed continue to be helpful to our visitors. If you find that a link isn't working or information is incorrect, please email infocenter@lls.org. If you would like for us to consider adding your organization to this resource, please complete and submit this form.

Doctor in white coat holding a patient's hands

A Starting Place to Prioritize Your Mental Health

Coping with a blood cancer diagnosis and the whirlwind of experiences that follows can be physically, mentally, and emotionally draining for everyone impacted by it.

Whether you're a patient or caregiver, you begin to realize your life will never be the same.

Cellular Crosstalk In The Normal And Malignant Bone Marrow

We want to understand how leukemia inhibits blood production as this is one of the main causes of death in leukemia patients. We use new microscopy techniques developed by our group to image—for the first time—all types of blood cells and how they are eradicated by leukemia cells. Identification of the mechanisms through which leukemia inhibits blood production will be the foundation for new studies to develop drugs to maintain normal blood levels and prevent death in leukemia patients.

Optimizing MICA/B antibody for AML by selective binding to Fc activating receptors

Acute myeloid leukemia (AML) is a blood cancer characterized by poor clinical outcomes. We developed an antibody that inhibits AML in models by triggering anti-leukemia immunity. Now we developed a new version of this antibody with higher affinity to the leukocyte receptors that mediate anti-leukemia immunity. We will establish the ability of this optimized antibody to elicit greater inhibition of AML. The studies will generate important information about how to induce anti-leukemia immunity.

Aberrant LZTR1 and RIT1 signaling as a driver of clonal hematopoietic disorders

Our research focuses on a novel mechanism of RAS protein regulation via the protein LZTR1, which is altered in leukemia and hinders the effectiveness of leukemia therapies. We will utilize mouse models and functional genomic studies to uncover how altered RAS degradation drives leukemia and identify novel drug targets. This effort will help us identify the clinical impact of alterations in this novel RAS pathway in patients and potential means to improve leukemia treatment.

LLS Podcast

Being diagnosed with a blood cancer can make you feel like you are alone. The Bloodline with LLS is here to remind you that after a diagnosis comes hope. Listen in as experts and patients guide listeners in understanding diagnosis, treatment, and resources available to blood cancer patients. Join The Patient Education Team at The Leukemia & Lymphoma Society as they explore various survivorship topics.

Investigating the impact of hotspot mutations in a chromatin reader on leukemogenesis

The goal of this proposal is to investigate the consequence of the chromatin reader eleven-nineteen-leukemia (ENL) gain-of-function mutations in the pathogenesis of leukemia. Our studies leverage the expertise in the molecular and chromatin biology of chromatin reader in leukemia utilizing mouse model, high resolution image, epigenomic and transcriptomic approaches. Our goal is to understand how chromatin reader contributes to cancer development, progression, and therapeutic outcome.

Understanding and Overcoming Mechanisms of Immune Evasion after Allogeneic Transplant

Outcomes for patients with acute myelogenous leukemia who relapse after transplantation are dismal. This SCOR brings together an international group of collaborators with deep expertise in genomics, epigenetics, antigen presentation, and immune-regulation. They will focus on mechanisms of immune evasion by leukemia cells, identifying effective T cell responses to those evasive processes, and providing critical insights into the optimal approaches to model new and promising targets for immunotherapy with a goal of eliminating leukemia recurrence.  

Mechanisms of Pathogenesis by MYB Fusions in Blastic Plasmacytoid Dendritic Cell Neoplasm

The transcription factor MYB has long been associated with leukemia, but how it contributes to disease is poorly understood. Fusions of MYB to other proteins, causing MYB activation, are found in patients with Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN), but rare in other leukemias. I am using recently developed techniques to gain insight into how MYB fusions cause BPDCN. This will enable both new treatments for BPDCN and better understanding of the role of MYB in other leukemias.

Peer-to-Peer Support

Patti Robinson Kaufmann First Connection® Program

If you or a family member has been diagnosed with a blood cancer, you may find it helpful to speak with someone who has gone through a similar experience and learned how to manage the same disease you're trying to cope with each day. The Patti Robinson Kaufmann First Connection® Program is a free service of The Leukemia & Lymphoma Society (LLS) that introduces patients and their loved ones to a trained peer volunteer who has gone through a similar experience.

NK cell immunotherapy to reduce relapse after haploidentical transplant for high-risk pediatric AML

Leukemia recurrence remains the most common type of treatment failure after allogeneic hematopoietic cell transplant for children and young adults with high-risk acute myelogenous leukemia (AML), occurring in 40-50% of patients. Novel treatment strategies are needed to attain durable remissions and provide long-term cure. We have developed a novel memory-like (ML) NK cell immunotherapy that has demonstrated potent activity against AML in preclinical and early clinical studies.